Buffalo Grass Allergy Shots: A Dioecious Native With a Unique Pollen Fix
Buffalo grass allergy shots (SCIT) address Bouteloua dactyloides — the native Great Plains shortgrass with a unique biological advantage no other US lawn grass offers: it is dioecious, meaning separate male and female plants exist, and planting female-only cultivars eliminates lawn pollen production entirely.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Buffalo Grassis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Buffalo Grass Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to buffalo grass — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of buffalo grass allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of buffalo grass immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of buffalo grass extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for buffalo grass allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing buffalo grass extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription buffalo grass immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat buffalo grass allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Buffalo Grass?
The biology, taxonomy, and clinical fingerprint of Buffalo Grass — the foundation of how SCIT targets it.
Buffalo grass (Bouteloua dactyloides) shortgrass prairie in summer — the only major US lawn grass that is dioecious. Male plants produce pollen; female plants produce none. Female-only cultivars ('Density,' 'Legacy,' 'UC Verde') offer a complete pollen-elimination option for sensitized homeowners in the Great Plains and xeriscape gardens.
- Scientific name
- Bouteloua dactyloides (formerly Buchloe dactyloides)
- Family
- Poaceae (Chloridoideae)Grass family — warm-season Chloridoideae
- Type
- Perennial warm-season native shortgrass pollen — dioecious (separate male/female plants)
- Native to
- Great Plains of North America — Texas Panhandle through Nebraska, Kansas, Colorado, Wyoming, extending into Montana and the Dakotas
- Allergen proteins
- No WHO/IUIS-recognized allergens for Bouteloua dactyloides as of the 2024 nomenclature database — Group 1 beta-expansin inferred from Chloridoideae subfamily classification; no Group 5 allergens expected (Andersson & Lidholm, 2003; Esch & Bush, 2008)
- Particle size
- 25–32 μm
- Avoidance difficulty
- Moderate
How Buffalo Grass Allergy Presents
Symptoms by body system — useful for distinguishing Buffalo Grass sensitivity from overlapping allergies and infections.
Respiratory
- Seasonal sneezing and rhinorrhea during June–August Great Plains pollen season
- Nasal congestion in residents with male-plant buffalo grass lawns or near prairie restoration areas
- Respiratory irritation during peak pollen release in low-growth shortgrass prairie landscapes
- Potential asthma exacerbation during high-count prairie pollen events in Plains cities
Ocular
- Eye itching and tearing during June–August pollen events in Plains residential areas
- Conjunctival redness after outdoor activity near buffalo grass prairie restorations
- Mild light sensitivity during peak warm-season Plains pollen weeks
Dermal
- Mild skin irritation after contact with buffalo grass during outdoor prairie activity
- Rare contact urticaria in highly sensitized individuals during direct grass contact
Systemic
- Mild fatigue from warm-season allergy during the June–August Plains pollen window
- Sleep disruption from nasal congestion in Plains households with buffalo grass lawns
- Reduced outdoor exercise tolerance in highly sensitized Plains patients during peak pollen weeks
Buffalo grass is the one grass allergy situation where I open with a non-medical option: if the patient has a buffalo grass lawn, I ask whether they'd consider replanting with a female cultivar — 'Density' or 'Legacy' are widely available. Eliminating the male plants from the property removes the home pollen source entirely. Then we discuss whether a Bermuda-anchored SCIT vial is warranted for ambient Plains exposure.
When & Where Buffalo Grass Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: July across the Great Plains; limited NAB monitoring data for shortgrass prairie regions compared to urban monitoring sites· June–August across the central Plains; minimal pollen production from female-only cultivars regardless of season
US Exposure Map
6 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Moderate
- ND:
- Moderate
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- High
- SD:
- Moderate
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Moderate
- CO:
- High
- NE:
- High
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- Low
- NM:
- Moderate
- KS:
- High
- AR:
- Low
- TN:
- Low
- NC:
- Low
- SC:
- Low
- OK:
- High
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- High
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Buffalo Grass Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Buffalo grass (Chloridoideae) is presumed to share Group 1 beta-expansin cross-reactivity with Bermuda and related warm-season grasses based on subfamily classification, though no direct IgE inhibition studies between Bouteloua dactyloides and any other grass extract have been published.
Chloridoideae — nearest characterized relative with FDA-standardized extract; Bermuda serves as primary SCIT surrogate for buffalo grass
Panicoideae — cross-subfamily Group 1 cross-reactivity; lesser than within-Chloridoideae
Is SCIT Right for Your Buffalo Grass Allergy?
Answer five questions to assess your candidacy for empirical Chloridoideae SCIT for buffalo grass sensitization.
How severe are your warm-season grass allergy symptoms during June–August in the Plains?
The Buffalo Grass SCIT Protocol
No dedicated buffalo grass SCIT extract exists. Empirical treatment uses Bermuda grass (Cynodon dactylon) extract as the Chloridoideae surrogate, given the inferred Group 1 allergen homology between Bouteloua dactyloides and Cynodon dactylon. This approach is consistent with the Esch & Bush (2008) guidance that buffalo grass is covered empirically via Bermuda extract in a warm-season mix.
The Bermuda-anchored vial escalates from dilute to maintenance concentration under 30-minute post-injection observation. Because the buffalo grass season peaks in July across the Plains, beginning build-up in fall or winter allows reaching maintenance before the following summer. Your allergist will individualize dosing based on Cyn d 1 IgE and skin test results as the Chloridoideae proxy marker.
Ongoing maintenance sustains Chloridoideae tolerance through the Plains pollen season. Because buffalo grass pollen season is shorter (June–August) than Bermuda in the Sun Belt, some Plains patients may have a more discrete pre-seasonal build-up cycle. Female-only cultivar replacement, if feasible, reduces residential pollen exposure to near zero and is a meaningful adjunct to systemic SCIT.
Patients completing a full SCIT course typically experience sustained symptom reduction for years after stopping. The decision to plant female-only cultivars in the residential lawn is permanent and provides lasting environmental pollen reduction independent of immunotherapy status.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Buffalo Grass SCIT
No published clinical trial of any design has used buffalo grass extract as its primary SCIT intervention — the most data-sparse warm-season grass profile in US allergy practice. Efficacy for empirical Bermuda-anchored SCIT is extrapolated from the Bermuda SCIT RCT and Chloridoideae subfamily conservation principles.
- Bermuda SCIT nasal symptom reduction (applied as Chloridoideae class evidence)51%Tabar et al., 2005, J Investig Allergol Clin Immunol — Bermuda RCT used as Chloridoideae proxy
- Grass SCIT symptom reduction (meta-analysis, reference baseline)40%Calderón M et al., 2007, Cochrane Database Syst Rev
There is no buffalo grass SCIT RCT, no Bou d allergen series, and no IgE inhibition studies between buffalo and any other grass extract as of 2024. Esch & Bush (2008) explicitly classify buffalo grass as 'data sparse.' The most honest clinical guidance: for residential buffalo grass lawns, installing female-only cultivars is the evidence-nearest intervention available, providing complete residential pollen elimination with a high confidence margin. Empirical Bermuda-anchored SCIT addresses ambient Plains Chloridoideae exposure where female cultivar replacement does not reach.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Buffalo Grass SCIT Side Effects
Empirical Bermuda-anchored SCIT for buffalo grass sensitization carries the same local and systemic reaction profile as other inhalant SCIT, managed through the mandatory 30-minute post-injection observation period.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Wheal and flare at injection arm; resolves within hours | Rate 30–50% | Mild |
Injection-site itching Pruritus at injection site; cold compress provides relief | Rate 25–40% | Mild |
Large local reaction (>25 mm) May require dose adjustment; inform allergist before next visit | Rate 5–10% | Moderate |
Delayed induration Firm lump persisting 24–48 hours; resolves without treatment | Rate 2–5% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Nasal/conjunctival flare Brief worsening of baseline allergy symptoms post-injection | Rate 0.5–1% | Mild |
Generalized urticaria Managed with antihistamines; dose reduction at next visit | Rate 0.1–0.3% | Moderate |
Mild bronchospasm More likely in patients with poorly controlled asthma | Rate 0.1–0.2% | Moderate |
Systemic anaphylaxis Managed with epinephrine; at-home observation is the primary safety net | Rate <0.01% | Severe |
No deaths from inhalant SCIT have been reported in the US in the past decade with proper 30-minute post-injection observation protocols. Bermuda extract used as the Chloridoideae surrogate for buffalo grass sensitization carries the well-established Bermuda SCIT safety profile.
SCIT vs Alternatives for Buffalo Grass
Great Plains patients with buffalo grass sensitization have a uniquely layered option set — including a complete home-lawn pollen elimination strategy not available for any other US grass species.
| Criterion | At-Home SCIT (Curex)Best | SLIT | Female-cultivar replacement | Medications |
|---|---|---|---|---|
| Effectiveness | Empirical disease-modifying via Bermuda proxy; class evidence 40–51% | Moderate — no buffalo grass SLIT; Bermuda proxy drops available | Complete — eliminates residential pollen entirely for lawn source | Symptom suppression only |
| 5-yr cost | $3,500–$10,000 | $1,500–$4,000 | Lawn installation cost | $500–$3,000 |
| Duration | 3–5 years | 3–5 years | Permanent | Indefinite daily use |
| Convenience | At-home self-injection; same weekly build-up then monthly cadence | Daily drops at home | One-time lawn renovation | Easy — oral/nasal |
| Safety | Virtual Shot Room–supervised first dose + prescribed epi on hand; <0.01% anaphylaxis | Very low systemic risk | Excellent | Generally safe; drowsiness risk |
| Lasting effect | 7–12+ years post-course | Moderate lasting effect | Permanent pollen elimination from lawn | None — symptoms return off medication |
At-Home SCIT (Curex)Best
SLIT
Female-cultivar replacement
Medications
For buffalo grass lawn owners, the combination of female-only cultivar replacement (eliminating the residential pollen source) and empirical Bermuda-anchored SCIT (addressing ambient Plains Chloridoideae exposure) provides the most comprehensive management strategy. Curex now delivers that Bermuda-anchored SCIT as an at-home allergy shot with pricing confirmed in a current program quote: a personalized Chloridoideae serum compounded under USP <797> using Bermuda as the proxy, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, a prescribed epinephrine auto-injector confirmed on hand, and week-by-week dose escalation overseen by a board-certified allergist — so patients unable to access regular clinic visits manage ambient Plains warm-season grass exposure at home.
What Buffalo Grass SCIT Actually Costs
Most major US insurers cover warm-season grass SCIT under standard allergy benefits. Curex's at-home Cyn d 1 IgE testing can document Chloridoideae sensitization as the proxy marker for buffalo grass, supporting prior authorization without requiring an initial office visit. Rural Plains patients should verify in-network allergist availability before beginning treatment planning.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your buffalo grass allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Buffalo Grass SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Buffalo grass (Bouteloua dactyloides) is a dioecious species — meaning separate male plants produce pollen and female plants produce none. This is a unique biological trait among major US lawn grasses, which are typically either monoecious (both sexes on the same plant) or self-pollinating. Female-only cultivars commercially available in the US include 'Density,' 'Legacy,' 'UC Verde,' '609,' and 'Tatanka' — all are certified to contain only female plants (Texas A&M Turfgrass Program, 2022). Installing a buffalo grass lawn using these cultivars eliminates lawn pollen production entirely from the residential landscape. This is the only certified pollen-elimination lawn strategy for any native US grass, and it requires no ongoing medical management for the home-source component of buffalo grass exposure.
No dedicated buffalo grass SCIT extract is commercially available, and no Bouteloua dactyloides-specific allergens have been named in the WHO/IUIS database as of 2024. Esch & Bush (2008) in Middleton's Allergy classified buffalo grass as 'data sparse' among US grass allergens. In clinical practice, allergists manage presumed buffalo grass sensitization empirically using Bermuda grass extract (Cynodon dactylon) as a Chloridoideae surrogate, based on the subfamily conservation of Group 1 beta-expansin allergens. Testing uses Cyn d 1 serum IgE or Bermuda skin prick test as the proxy marker. This is standard practice for data-sparse allergens with no dedicated extract, and the approach is consistent with the Joint Task Force Practice Parameter framework for empirical immunotherapy.
Both buffalo grass and Bermuda grass belong to the Chloridoideae subfamily of Poaceae and share the same fundamental allergen architecture — Group 1 beta-expansin allergens and no Group 5 proteins. However, they differ in several clinically relevant ways. Bermuda grass (Cynodon dactylon) is a cosmopolitan Sun Belt turf grass with nine named WHO/IUIS allergens, an FDA-standardized extract, and a published randomized controlled SCIT trial. Buffalo grass (Bouteloua dactyloides) is a native North American shortgrass with no named allergens, no dedicated extract, and zero published SCIT trial data. Buffalo grass is also dioecious — its female-only cultivar option has no equivalent in Bermuda. Geographically, Bermuda dominates the Sun Belt while buffalo grass dominates the central Great Plains from Texas northward.
As a Chloridoideae pollen allergen, buffalo grass can theoretically trigger or exacerbate allergic asthma through the same IgE-mediated airway inflammation mechanisms shared by all grass pollens. However, no published epidemiological study has directly linked buffalo grass sensitization to asthma incidence or exacerbation rates independently of other Great Plains warm-season grass pollens. The sparse allergen characterization and absence of Bou d-specific molecular testing make it difficult to isolate buffalo grass's contribution from concurrent Johnson grass, Bermuda, or temperate grass sensitization that coexists in many Plains allergy patients. A board-certified allergist can evaluate your overall grass sensitization profile and assess asthma control as part of candidacy evaluation for empirical warm-season grass SCIT.
Yes — buffalo grass is an increasingly popular choice for native prairie restoration projects, xeriscape landscaping, and drought-tolerant public-space turf replacement across the Great Plains and intermountain West. Denver Water includes it on its rebate-eligible turf list as a water-conserving alternative to Kentucky bluegrass. Municipal parks, highway medians, and school grounds in Colorado, Kansas, Nebraska, and Oklahoma are increasingly replacing irrigated exotic turf with native buffalo grass. If the restoration uses mixed-sex seed rather than certified female-only cultivars, the male plants in these restoration areas can serve as ambient pollen sources for nearby residents. Requesting female-only certified seed for public restoration projects is an advocacy step that allergy-aware Plains residents can take with municipal landscaping departments.
Skin prick testing for buffalo grass may be available from some allergists using a non-standardized buffalo grass extract, but this is uncommon in most allergy practices due to the scarcity of commercial buffalo grass-specific extract. The more practical diagnostic approach is Cyn d 1 serum IgE testing (ImmunoCAP g2/Bermuda component), which serves as a Chloridoideae proxy marker for buffalo grass sensitization given the inferred Group 1 conservation between the two Chloridoideae species. A positive Cyn d 1 result in a Great Plains patient with warm-season grass symptoms and buffalo grass residential exposure provides sufficient clinical basis for initiating empirical Bermuda-anchored SCIT, per the Esch & Bush (2008) guidance.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.